Home » Stocks » GRCL

Gracell Biotechnologies, Inc. (GRCL)

Stock Price: $22.50 USD -1.50 (-6.25%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $22.49 -0.01 (-0.04%) Jan 19, 5:52 PM
Market Cap 1.54B
Revenue (ttm) n/a
Net Income (ttm) -25.20M
Shares Out 65.56M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $22.50
Previous Close $24.00
Change ($) -1.50
Change (%) -6.25%
Day's Open 24.01
Day's Range 21.08 - 24.62
Day's Volume 621,187
52-Week Range 21.08 - 25.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 17 hours ago

SUZHOU and SHANGHAI, China, Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing hig...

PRNewsWire - 4 days ago

SUZHOU, China, Jan. 15, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacio...

PRNewsWire - 6 days ago

SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing hig...

Bloomberg Markets and Finance - 1 week ago

China's Gracell Biotechnologies Lists on Nasdaq

Jan.10 -- William Cao, founder and chief executive officer of Gracell Biotechnologies, discusses the Shanghai-based company's initial public offering in the U.S. and its growth strategy. Grace...

Seeking Alpha - 1 week ago

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a dea...

Other stocks mentioned: ARGX, EYPT, GILD, INO, LLY, PRTK, ZLAB
PRNewsWire - 1 week ago

SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and ...

NASDAQ - 2 weeks ago

Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, announced terms for its US IPO on Monday. The Suzhou, China-based company plans to raise $150 mil...

NASDAQ - 1 month ago

Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

SEC - 1 month ago

Gracell Biotechnologies, Inc. has filed to go public with an IPO on the NASDAQ.

PRNewswire - 1 month ago

Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and...

About GRCL

Gracell Biotechnologies, a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL... [Read more...]

Industry
Biotechnology
IPO Date
Jan 8, 2021
CEO
William Wei Cao, Ph.D. B.M.
Employees
160
Stock Exchange
NASDAQ
Ticker Symbol
GRCL
Full Company Profile

Financial Performance

Financial numbers in millions CNY.
Financial Statements